Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies

Background and objectives: Patients with myeloproliferative disease (MPD) have an increased risk of thrombosis. We studied markers of platelet and coagulation activation in a large cohort of patients with MPD (n = 118) and related this to Janus Kinase 2 (JAK2) V617 F mutation status, a marker of clo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2007-08, Vol.5 (8), p.1679-1685
Main Authors: ROBERTSON, B., URQUHART, C., FORD, I., TOWNEND, J., WATSON, H. G., VICKERS, M. A., GREAVES, M.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Antiphospholipid - chemistry
antiphospholipid
Blood Coagulation
Blood Platelets - cytology
Blood Platelets - metabolism
clonality
Cohort Studies
Female
Humans
Janus Kinase 2 - genetics
Male
Middle Aged
mutation
myeloproliferative
Myeloproliferative Disorders - genetics
Myeloproliferative Disorders - metabolism
platelet
thrombosis
Thrombosis - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and objectives: Patients with myeloproliferative disease (MPD) have an increased risk of thrombosis. We studied markers of platelet and coagulation activation in a large cohort of patients with MPD (n = 118) and related this to Janus Kinase 2 (JAK2) V617 F mutation status, a marker of clonality, and the presence of antiphospholipid antibodies (APA), all of which have been associated with thrombosis in MPD. Methods: D‐dimer, thrombin–antithrombin complexes (TAT), prothrombin fragments 1 + 2 (F1+2), soluble E‐selectin (sE‐selectin), and soluble P‐selectin (sP‐selectin) levels were compared between patients and hypertensive controls (n = 127). Assays for lupus anticoagulant (LA), anticardiolipin antibodies (ACA), antibeta2 glycoprotein 1 antibodies (anti‐β2GP1), and antiprothrombin antibodies (α‐Pro) were also performed. The JAK2 V617F mutation status was determined in the cohort using amplification refractory mutation system (ARMS) polymerase chain reaction. Disease clonality was determined in 54 patients using the HUMARA assay. Results: sP‐selectin was significantly increased in patients with MPD (P ≤ 0.001). sP‐selectin levels were significantly elevated in JAK2 V617F‐positive patients compared to wild‐type (P = 0.006), or controls (P 
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/j.1538-7836.2007.02626.x